Trial Profile
Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-Adjuvant to Induction-Concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 04 Jun 2020 Results assessing therapeutic effect of changing to an induction-concurrent sequence or accelerated-fractionation sequence, and/or replacing 5-fluorouracil with capecitabine, published in the Cancer.
- 05 Aug 2019 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.